Drug Delivery News and Research RSS Feed - Drug Delivery News and Research

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.
Lupin introduces new InspiraChamber VHC under strategic licensing agreement with InspiRX

Lupin introduces new InspiraChamber VHC under strategic licensing agreement with InspiRX

Pharma Major Lupin Limited announced today that its US subsidiary, Lupin Pharmaceuticals Inc. (collectively Lupin) has launched the all new InspiraChamber Anti-Static Valved Holding Chamber (VHC) under a strategic licensing agreement with the New Jersey based respiratory research and development company InspiRX Inc. [More]
Study findings could help scientists better design silicon materials to improve chemotherapy drug delivery

Study findings could help scientists better design silicon materials to improve chemotherapy drug delivery

A team of Israeli and American researchers have found that silicon nanomaterials used for the localized delivery of chemotherapy drugs behave differently in cancerous tumors than they do in healthy tissues. The findings could help scientists better design such materials to facilitate the controlled and targeted release of the chemotherapy drugs to tumors. [More]
Biomedical use of gold nanotubes demonstrated in mouse model of human cancer

Biomedical use of gold nanotubes demonstrated in mouse model of human cancer

Scientists have shown that gold nanotubes have many applications in fighting cancer: internal nanoprobes for high-resolution imaging; drug delivery vehicles; and agents for destroying cancer cells. [More]
Study shows targeted therapeutic after chemotherapy kills transitional cancer cells

Study shows targeted therapeutic after chemotherapy kills transitional cancer cells

Timing may be decisive when it comes to overcoming cancer's ability to evade treatment. By hitting breast cancer cells with a targeted therapeutic immediately after chemotherapy, researchers from Brigham and Women's Hospital (BWH) were able to target cancer cells during a transitional stage when they were most vulnerable, killing cells and shrinking tumors in the lab and in pre-clinical models. [More]
NanoSmart's ANA-conjugated liposomal doxorubicin receives FDA Orphan Drug Designation

NanoSmart's ANA-conjugated liposomal doxorubicin receives FDA Orphan Drug Designation

NanoSmart Pharmaceuticals, Inc., a private pharmaceutical company developing nanoparticle drug delivery platforms, has received Orphan Drug Designation from the Food and Drug Administration for one of its lead candidates, antinuclear antibody (ANA) conjugated liposomal doxorubicin. [More]
New NIH grant to help restore function after spinal cord injury

New NIH grant to help restore function after spinal cord injury

Restoring function after spinal cord injury, which damages the connections that carry messages from the brain to the body and back, depends on forming new connections between the surviving nerve cells. While there are some delicate surgical techniques that reconnect the nerves, researchers are also looking at ways to restore the connections themselves at a cellular level. [More]
New stent for treating cardiovascular disease successfully implanted in patients

New stent for treating cardiovascular disease successfully implanted in patients

A new stent for treating cardiovascular disease that incorporates a polymer invented at Rutgers, The State University of New Jersey, has been implanted in patients for the first time. [More]
Five researchers selected to receive 2015 Avant-Garde Award for HIV/AIDS Research

Five researchers selected to receive 2015 Avant-Garde Award for HIV/AIDS Research

With proposals ranging from innovative therapies to the development of unique organoid models of the brain, five scientists have been selected to receive the 2015 Avant-Garde Award for HIV/AIDS Research from the National Institute on Drug Abuse, part of the National Institutes of Health. The five scientists will each receive $500,000 per year for five years to support their research. [More]

Cohera Medical gets FDA approval to distribute TissuGlu Surgical Adhesive in US

Cohera Medical, Inc.®, a leading innovator and developer of surgical adhesives and sealants, announced today that the U.S. Food and Drug Administration (FDA) has approved its TissuGlu® Surgical Adhesive. [More]
New findings could pave way to develop drug therapies for necrosis-related diseases

New findings could pave way to develop drug therapies for necrosis-related diseases

Strokes, heart attacks and traumatic brain injuries are separate diseases with certain shared pathologies that achieve a common end - cell death and human injury due to hypoxia, or lack of oxygen. [More]
Chili peppers show promise as diet-based supplement

Chili peppers show promise as diet-based supplement

Don't go chomping on a handful of chili peppers just yet, but there may be help for hopeful dieters in those fiery little Native American fruits. [More]
BD reports quarterly revenues of $2.051 billion for first fiscal quarter 2014

BD reports quarterly revenues of $2.051 billion for first fiscal quarter 2014

BD (Becton, Dickinson and Company), a leading global medical technology company, today reported quarterly revenues of $2.051 billion for the first fiscal quarter ended December 31, 2014, representing an increase of 1.8 percent from the prior-year period, or 5.3 percent on a foreign currency-neutral basis. [More]
Researchers devise new technique to deliver cancer treatment

Researchers devise new technique to deliver cancer treatment

A team of researchers has devised a new way to target tumors with cancer-fighting drugs, a discovery that may lead to clinical treatments for cancer patients. [More]
MedImmune, University of Manchester sign new research collaboration

MedImmune, University of Manchester sign new research collaboration

MedImmune, the global biologics research and development arm of AstraZeneca, and The University of Manchester have entered into a new research collaboration to generate cutting-edge protein formulation science. [More]
Research describes new way of shrinking ovarian cancer tumors, improving drug delivery

Research describes new way of shrinking ovarian cancer tumors, improving drug delivery

New research published in the February 2015 issue of The FASEB Journal, may eventually help improve the five-year survival rate of ovarian cancer patients by describing a new way of shrinking ovarian cancer tumors while also simultaneously improving drug delivery. [More]
Project Spark to advance neuroprotective drug for schizophrenia-associated cognitive impairment

Project Spark to advance neuroprotective drug for schizophrenia-associated cognitive impairment

A public-private consortium led by the biotech Iproteos -based at Parc Científic de Barcelona (PCB)-, and comprised by the biopharmaceutical company Ascil-Biopharma, the Institute for Biomedical Research (IRB Barcelona), the Centre for Genomic Regulation (CRG) and the University of the Basque Country (UPV/EHU) has launched a project to advance the development of a new neuroprotective drug for the treatment of the cognitive impairment associated with schizophrenia and other mental disorders. [More]
Micromotor fueled by stomach acid effectively delivers gold nanoparticles

Micromotor fueled by stomach acid effectively delivers gold nanoparticles

Researchers at the University of California, San Diego have shown that a micromotor fueled by stomach acid can take a bubble-powered ride inside a mouse. These tiny motors, each about one-fifth the width of a human hair, may someday offer a safer and more efficient way to deliver drugs or diagnose tumors. [More]
Nuvo Research announces topline results from WF10 Phase 2 allergic rhinitis clinical trial

Nuvo Research announces topline results from WF10 Phase 2 allergic rhinitis clinical trial

Nuvo Research Inc., a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced the results of its 16-week, double-blind, placebo-controlled, Phase 2 clinical trial conducted in Germany to compare the safety and efficacy of WF10 and its main constituents (sodium chlorite and sodium chlorate) with saline in patients with refractory allergic rhinitis and to compare the safety and efficacy of WF10 and its main constituents. [More]
Researchers create customized soap bubbles that promote drug and vaccine delivery

Researchers create customized soap bubbles that promote drug and vaccine delivery

When University of Maryland Professors Philip DeShong and Daniel Stein began tagging soap bubbles with biomolecules, they had no idea this technology would one day be poised to change the way drugs and vaccines fight against bacteria, viruses and cancer. [More]
Attaching Epirubicin drug to nanodiamonds eliminates chemoresistant cancer stem cells

Attaching Epirubicin drug to nanodiamonds eliminates chemoresistant cancer stem cells

A study led by the National University of Singapore found that attaching chemotherapy drug Epirubicin to nanodiamonds effectively eliminates chemoresistant cancer stem cells. The findings were first published online in ACS Nano, the official journal of the American Chemical Society, in December 2014. [More]
Advertisement
Advertisement